| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447461 | European Journal of Cancer | 2011 | 7 Pages |
Abstract
In a large population of children with high risk ALL who received dexrazoxane as a cardioprotectant drug, the occurrence of secondary AML was a rare event.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lynda M. Vrooman, Donna S. Neuberg, Kristen E. Stevenson, Barbara L. Asselin, Uma H. Athale, Luis Clavell, Peter D. Cole, Kara M. Kelly, Eric C. Larsen, Caroline Laverdière, Bruno Michon, Marshall Schorin, Cindy L. Schwartz, Harvey J. Cohen,